Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a breath of oxygen boost walking stamina in lung disease?

NCT ID NCT07777367

Symptom relief Sponsor: Silvia Ulrich Somaini Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Sep 09, 2026 · Updated 2 times

Summary

This trial asks whether breathing supplemental oxygen during a 6-minute walk test helps people with pulmonary vascular disease (PAH or CTEPH) walk farther than they would on ambient air. Participants will complete two walk tests—one with oxygen via nasal cannula and one without—to compare distance and oxygen levels. The goal is to see if commonly prescribed oxygen therapy truly improves exercise performance in this group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Supplemental liquid oxygen therapy (LOX) given via nasal cannula at about 4 liters per minute during a 6-minute walk test
What this could lead to
If supplemental oxygen improves walking distance, it could support its routine use during exercise for people with pulmonary vascular disease.
What could go wrong
The trial is small (40 participants) and early, so results may not apply to everyone. Oxygen therapy can have side effects like nasal dryness or discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Minimum 18 years of age * Written informed consent * Patients with diagnosed pulmonary arterial hypertension (PAH), distal chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD) with emphysema, COPD without emphysema, or interstitial lung disease * Former desaturation under exercise defined as SpO2-decrease \>3% * Treated with a stable drug therapy (with no changes for at least 14 days prior to screening) Exclusion Criteria: * Severe hypoxemia needing supplemental oxygen therapy defined as PaO2 \< 6.9 kPa * Inability or contraindications to undergo the investigated intervention * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, walk disability etc.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic thromboembolic pulmonary hypertension (cteph) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic thromboembolic pulmonary hypertension pulmonary arterial hypertension pulmonary artery disease pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic thromboembolic pulmonary hypertension (cteph) Pulmonary arterial hypertension (PAH) Pulmonary vascular disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Zurich

    RECRUITING

    Zurich, Canton of Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.